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CASE REPORT
Macular hole formation 
following intravitreal injection of ranibizumab 
for branch retinal vein occlusion: a case report
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Abstract 
Background: Macular hole formation after anti-vascular endothelial growth factor therapy is a rare complication. We 
report macular hole formation after intravitreal ranibizumab injection for branch retinal vein occlusion.
Case presentation: A 63-year-old Asian male was treated with intravitreal ranibizumab injection for chronic macular 
edema with branch retinal vein occlusion in his right eye. Before treatment, best-corrected visual acuity in his right 
eye was 20/200. Nine days after injection, a full thickness macular hole developed with reduction of macular edema. 
After pars plana vitrectomy combined with cataract surgery, the macular hole was successfully closed, and the best-
corrected visual acuity in his right eye improved to 20/40.
Conclusion: The possibility of an infrequent complication like macular hole should be considered for intravitreal 
ranibizumab for macular edema with branch retinal vein occlusion.
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Background
Retinal vein occlusion (RVO), including branch reti-
nal vein occlusion (BRVO), is a major retinal vascular 
disease. Macular edema is the most common cause of 
visual impairment in eyes with RVO. There are several 
treatment options for macular edema in RVO, including 
laser photocoagulation [1], intravitreal steroid treatment 
[2], and vitrectomy [3]. Recently, various anti-vascular 
endothelial growth factor (VEGF) therapies includ-
ing ranibizumab [4] (Lucentis®; Genentech, South San 
Francisco, CA, USA), aflibercept [5] (Eylea®; Regen-
eron, Tarrytown, PA, USA and Bayer HealthCare, Berlin, 
Germany), and bevacizumab [6] (Avastin®; Genentech) 
are widely used for the treatment of macular edema in 
RVO. Anti-VEGF therapy has shown favorable results for 
RVO [4–6], although adverse complications have been 
reported with this treatment [4]. We report a patient 
who developed a macular hole (MH) after ranibizumab 
injection for chronic BRVO, with closure of this macular 
hole after vitrectomy.
Case presentation
A 63-year-old Asian male, diagnosed with BRVO with 
refractory macular edema, was referred from his home 
doctor. His vision in his right eye had been slowly 
decreasing without any treatment for the previous 
5  years. The best-corrected visual acuity (BCVA) in his 
right eye was 20/200 and conventional fundus exami-
nation showed retinal hemorrhage followed by chronic 
BRVO in his right eye. He had a past history of hyperten-
sion, but no hyperlipidemia or diabetes mellitus. Optical 
coherence tomography (OCT) revealed serous retinal 
detachment and intraretinal edema that was located at 
the outer retina (Fig. 1a). Central retinal thickness (CRT) 
from the OCT B-scan image was 542 µm. Using fluores-
cein angiography imaging, a small capillary nonperfu-
sion area with collateral vessel formation was detected in 
the early phase, and dye leakage in the area of the vein 
occlusion was detected in the late phase (Fig. 1c, d). Slit 
lamp biomicroscopy revealed that the posterior vitreous 
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Fig. 1 B-scan optical coherence tomography (OCT) and color fundus photography before and after treatment. a, b Findings in the right eye before 
intravitreal administration of ranibizumab for chronic branch retinal vein occlusion. Serous retinal detachment and macular edema were located at 
the outer retina. c, d Fluorescein angiography revealed a capillary nonperfusion area and dye leakage in the late phase. e, f Nine days after injection 
of ranibizumab, OCT and color fundus photography showed formation of a full thickness macular hole and decreasing intraretinal edema. g, h Five 
months after surgery, the macular hole was closed and macular edema decreased
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cortex was attached on the macula. After obtaining 
informed consent, the patient was administered 0.5  mg 
ranibizumab intravitreally using a 32 gauge needle. Nine 
days after injection, BCVA in his right eye improved to 
20/100. OCT showed the formation of a full thickness 
MH and decreasing intraretinal edema (Fig. 1e). Twenty-
two days after injection, BCVA further recovered to 
20/50, but the MH was still open. The patient underwent 
25 gauge pars plana vitrectomy, combined with cataract 
surgery and intraocular lens implantation. Internal lim-
iting membrane peeling, photocoagulation to the non-
perfusion area, and gas tamponade using 20  % sulfur 
hexafluoride were successfully performed. One day after 
surgery, OCT confirmed successful closure of the MH. 
Five months after surgery, BCVA recovered to 20/40 and 
CRT decreased to 272 μm (Fig. 1g).
Discussion
There have been several reports of MH formation after 
intravitreal anti-VEGF therapy [7–12]. They included 
myopic choroidal neovascularization [7], age-related 
macular degeneration (AMD) [8–10], polypoidal choroi-
dal vasculopathy [11], and hemicentral retinal vein occlu-
sion [12]. However, to the best of our knowledge, this is a 
first report of MH formation after anti-VEGF therapy for 
BRVO.
The mechanism of MH formation after choroidal neo-
vascularization (CNV) treatment may have involved the 
rapid volume reduction of CNV after anti-VEGF therapy 
[7, 8]. However, Grigoropoulos et  al. [10] described the 
cause of MH formation as a force not only to the retinal 
pigment epithelium (RPE), but also to the retinal surface. 
Querques et al. [9] reported increasing vitreous macular 
traction after ranibizumab injection, with formation of a 
stage 2 MH. In AMD treatment with anti-VEGF therapy, 
the responsible factors for MH formation were assumed 
to exist at the RPE, retinal surface, and vitreous [7].
Nagpal et  al. reported MH formation after bevaci-
zumab injection to a hemi-central retinal vein occlusion 
patient. In this patient, rapid posterior vitreous detach-
ment (PVD) after injection was a possible causative fac-
tor for the development of the MH [12]. In our case, the 
PVD itself might not have been a causative factor for MH 
formation, because PVD was induced with active aspira-
tion during surgery. However, as in former reports, there 
was a possibility of vitreous macular traction.
The expression of transforming growth factor 
(TGF)-β2, which is known to cause fibrosis, was reported 
after anti-VEGF therapy [13, 14]. In proliferative diabetic 
retinopathy, acceleration of pathologic fibrosis by anti-
VEGF therapy was also reported [15]. In our case, acute 
regression of macular edema and increased fibrosis 
might have triggered a mechanical force to the damaged 
retina, and might have been a possible cause of MH 
formation.
Conclusions
Anti-VEGF therapy is a powerful and standard modal-
ity for management of macular edema following BRVO. 
However, the possibility of infrequent complications like 
MH should be considered after intravitreal injection of 
ranibizumab.
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Written informed consent was obtained from the patient 
for publication of this Case Report and any accompany-
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review by the Editor-in-Chief of this journal.
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